This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
EYLEA 2 mg is indicated for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).
DOSING WITH EYLEA 2 mg
Adapted from EYLEA 2 mg Summary of Product Characteristics.
EYLEA 2 mg posology in mCNV
The recommended dose for EYLEA is a single intravitreal injection of 2 mg aflibercept equivalent to 0.05 mL. Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. The schedule for monitoring should be determined by the treating physician. The interval between two doses should not be shorter than one month.
Abbreviations
DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. nAMD, neovascular age-related macular degeneration. RVO, retinal vein occlusion.
Footnote
*The diagram is for illustrative purposes only.
PP-EYL-GB-2341 | August 2024
- Referencesexpand_less
- 1EYLEA® 40 mg/mL Summary of Product Characteristics.